Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular oedema (DME) who don't respond to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback